Clinical Trials
54
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 100
- Registration Number
- NCT07141004
- Locations
- 🇮🇳
P. D. Hinduja National Hospital and Research Center, Mumbai, India
🇮🇳Sir Ganga Ram Hospital, New Delhi, India
🇮🇳Cims Hospital, Ahmedabad, India
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 75
- Registration Number
- NCT07030517
- Locations
- 🇮🇳
All India Institute of Medical Sciences, New Delhi, India
🇮🇳M S Ramaiah Medical College and Hospital, Bangalore, India
🇮🇳Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh, India
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 276
- Registration Number
- NCT04288778
- Locations
- 🇮🇳
Lifecare Hospital and Research Centre, Bengaluru, India
🇮🇳Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh, India
🇮🇳Kovai Diabetes Specialty Centre & Hospital, Coimbatore, India
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 150
- Registration Number
- NCT03768960
- Locations
- 🇮🇳
Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh, India
🇮🇳Avron Hospitals Pvt. Ltd, Ahmedabad, India
🇮🇳M S Ramaiah Medical College and Hospital, Bengaluru, India
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 100
- Registration Number
- NCT03733925
- Locations
- 🇮🇳
ChanRe Rheumatology And Immunology Center And Research, Bangalore, India
🇮🇳Apollo Hospitals, Bhubaneswar, India
🇮🇳Chennai Meenakshi Multispeciality Hospital, Chennai, India
- Prev
- 1
- 2
- Next